Tratamento desafiador no controle de crises epilépticas em cão refratário ao fenobarbital

Epilepsy is characterized by recurrent and unpredictable seizures, unlike the term seizure, which refers only to the clinical manifestation of abnormal brain electrical activity. In dogs, it is the most common neurological disorder and may have idiopathic, congenital, or secondary causes. This study reports the case of a five-year-old male mixed-breed dog that presented seizure episodes and was initially treated with phenobarbital. Despite the dosage adjustment, the dog continued to present seizures, suggesting refractivity to phenobarbital. Therefore, with the persistence of the episodes, potassium bromide was introduced, along with Epi Control®, to control the intensity of the seizures, and the supplement Aliv Pet®, which contains palmitoylethanolamide (PEA), a compound with anti-inflammatory and neuroprotective properties. The therapeutic combination showed good response, controlling the frequency of the episodes. The case highlights the importance of clinical diagnosis and laboratory tests, in addition to continuous monitoring and exploration of therapeutic alternatives to improve the patient's quality of life. The prognosis depends on the response to treatment and the frequency of seizures; in general, refractory patients can live a long life with good quality.